Lpath's Product Pipeline
Our Proprietary ImmuneY2™ Technology
Provides a Valuable Pipeline
|
| |
iSONEP™ |
ASONEP™ |
Lpathomab™ |
Nextomabs |
| Partnership Status |
 |
Pfizer Right of First Refusal |
Will consider a partnership |
Will consider a partnership |
| Target |
Sphingosine 1 Phosphate (S1P) |
Sphingosine 1 Phosphate (S1P) |
Lysophosphatidic Acid (LPA) |
Other bioactive lipids |
| Lead Indications |
Wet AMD, RPE Detachment, Diabetic Retinopathy |
Cancer, MS, INflammation, Colitis |
CNS Disorders, Pain, Fibrosis |
Inflammation, Cancer, Ocular |
| Clinical Status |
Phase 2s |
Entering Ph.2 in 2012 |
IND and Ph. 1 in 2012/2013 |
INDs in 2013 and beyond |
